Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small-cell lung cancer in a phase II randomized study.
about
Chemotherapy for advanced non-small cell lung cancer in the elderly populationSecond or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced diseaseSecond or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced diseaseClinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic reviewPaclitaxel, cisplatin, and gemcitabine combination chemotherapy within a multidisciplinary therapeutic approach in metastatic nonsmall cell lung carcinoma.Combination of paclitaxel and etoposide in the treatment of advanced non-small cell lung cancer: a phase I-II study.A randomized study comparing two different schedules of administration of cisplatin in combination with gemcitabine in advanced nonsmall cell lung carcinoma.Randomised phase II study of docetaxel/cisplatin vs docetaxel/irinotecan in advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group Study (WJTOG9803).A 21-day schedule of gemcitabine and cisplatin administration in the treatment of advanced non-small cell lung carcinoma: a phase II studyTreatment of advanced non small cell lung cancer in routine care: a retrospective analysis of 212 consecutive patients treated in a community based oncology group practicePulmonary delivery of cisplatin-hyaluronan conjugates via endotracheal instillation for the treatment of lung cancer.Novel combination chemotherapy in the treatment of non-small cell lung cancer.The case for the introduction of new chemotherapy agents in the treatment of advanced non small cell lung cancer in the wake of the findings of The National Institute of Clinical Excellence (NICE).Where to go with new expensive treatments in NSCLC.Combination therapy versus single agent chemotherapy in non-small cell lung cancer.Gemcitabine plus vinorelbine in advanced non-small cell lung cancer: a phase II study of three different doses. Gem Vin Investigators.First-line gemcitabine with cisplatin or epirubicin in advanced non-small-cell lung cancer: a phase III trial.Is gemcitabine cost effective in cancer treatment?
P2860
Q24186466-CCBBB37B-422C-4590-893A-DEF6B3F54931Q24200518-4A0C7631-C143-4DAA-897D-2E2C5A84B068Q24243664-39AD762F-688E-4055-9DD4-0C2471DE6D50Q24678961-4D923336-1474-4E33-B85D-0DC98E2C8867Q31791219-54965777-DA84-4A23-B1A6-8F0BD971DC66Q32100779-0FCD5311-0234-44D6-8145-652EA20922F0Q33334777-C3709ED4-4947-495D-A6ED-4368BD1F5261Q33358448-3E8C409D-953A-4954-93C1-D726EFC1DD4FQ33389166-D5B40B71-3BA7-42FE-B154-C959F8257683Q33860259-AA8BFB9A-57F8-439C-BC24-CB251C147FDFQ33862921-0D4787F3-4BDE-464E-AC63-F2215C2173BDQ34181910-DABDA2BA-A8EB-4CD4-BFE6-A26E174E7496Q34791240-8F7303F2-2041-4F9F-B6F8-339710E09D4AQ36114674-8549511C-C98E-4BDD-BBD4-858CAC9C2920Q36222050-B367C2D8-6BEC-4DDB-A137-6C977CF01460Q36621904-6BDF56CD-9D04-4FAA-9A5E-65B5861FAACDQ36671151-2A32E197-AF34-4CBD-A006-27602BBD1E72Q43042833-E07CE862-197B-4636-80CB-45F95127F2C0
P2860
Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small-cell lung cancer in a phase II randomized study.
description
1997 nî lūn-bûn
@nan
1997 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Gemcitabine versus the combina ...... n a phase II randomized study.
@ast
Gemcitabine versus the combina ...... n a phase II randomized study.
@en
type
label
Gemcitabine versus the combina ...... n a phase II randomized study.
@ast
Gemcitabine versus the combina ...... n a phase II randomized study.
@en
prefLabel
Gemcitabine versus the combina ...... n a phase II randomized study.
@ast
Gemcitabine versus the combina ...... n a phase II randomized study.
@en
P2093
P1476
Gemcitabine versus the combina ...... n a phase II randomized study.
@en
P2093
J Ming-Liu
J Whang-Peng
P304
P356
10.1200/JCO.1997.15.5.2097
P407
P577
1997-05-01T00:00:00Z